These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30928302)

  • 1. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.
    Olson HE; Demarest ST; Pestana-Knight EM; Swanson LC; Iqbal S; Lal D; Leonard H; Cross JH; Devinsky O; Benke TA
    Pediatr Neurol; 2019 Aug; 97():18-25. PubMed ID: 30928302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
    Kobayashi Y; Tohyama J; Takahashi Y; Goto T; Haginoya K; Inoue T; Kubota M; Fujita H; Honda R; Ito M; Kishimoto K; Nakamura K; Sakai Y; Takanashi JI; Tanaka M; Tanda K; Tominaga K; Yoshioka S; Kato M; Nakashima M; Saitsu H; Matsumoto N
    Brain Dev; 2021 Apr; 43(4):505-514. PubMed ID: 33436160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
    Demarest ST; Olson HE; Moss A; Pestana-Knight E; Zhang X; Parikh S; Swanson LC; Riley KD; Bazin GA; Angione K; Niestroj LM; Lal D; Juarez-Colunga E; Benke TA
    Epilepsia; 2019 Aug; 60(8):1733-1742. PubMed ID: 31313283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
    Olson HE; Daniels CI; Haviland I; Swanson LC; Greene CA; Denny AMM; Demarest ST; Pestana-Knight E; Zhang X; Moosa AN; Fidell A; Weisenberg JL; Suter B; Fu C; Neul JL; Percy AK; Marsh ED; Benke TA; Poduri A
    J Neurodev Disord; 2021 Sep; 13(1):40. PubMed ID: 34530725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Synaptic Bases of CDKL5 Disorder.
    Zhu YC; Xiong ZQ
    Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Providing quality care for people with CDKL5 deficiency disorder: A European expert panel opinion on the patient journey.
    Amin S; Møller RS; Aledo-Serrano A; Arzimanoglou A; Bager P; Jóźwiak S; Kluger GJ; López-Cabeza S; Nabbout R; Partridge CA; Schubert-Bast S; Specchio N; Kälviäinen R
    Epilepsia Open; 2024 Jun; 9(3):832-849. PubMed ID: 38450883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.
    MacKay CI; Wong K; Demarest ST; Benke TA; Downs J; Leonard H
    Clin Genet; 2021 Jan; 99(1):157-165. PubMed ID: 33047306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
    Lim Z; Wong K; Downs J; Bebbington K; Demarest S; Leonard H
    Epilepsy Res; 2018 Oct; 146():36-40. PubMed ID: 30071384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.
    Voronin G; Narasimhan J; Gittens J; Sheedy J; Lipari P; Peters M; DeMarco S; Cao L; Varganov Y; Kim MJ; Pear L; Fotouh E; Sinha S; Ray B; Wu MC; Yalamanchili P; Southgate C; Pick J; Saadipour K; Jung S; Lee J; Mollin A; Welch EM; Wu Z; Weetall M
    Mol Ther; 2024 Oct; 32(10):3331-3345. PubMed ID: 39033321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKL5 deficiency disorder in males: Five new variants and review of the literature.
    Siri B; Varesio C; Freri E; Darra F; Gana S; Mei D; Porta F; Fontana E; Galati G; Solazzi R; Niceta M; Veggiotti P; Alfei E
    Eur J Paediatr Neurol; 2021 Jul; 33():9-20. PubMed ID: 33989939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress on the pathogenesis of CDKL5 pathogenic variants and related encephalopathy.
    Sun X; Wang T
    Eur J Pediatr; 2023 Jul; 182(7):3049-3056. PubMed ID: 37166538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
    Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
    Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
    Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
    Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First report of Tunisian patients with CDKL5-related encephalopathy.
    Charfi Triki C; Zouari Mallouli S; Ben Jdila M; Ben Said M; Kamoun Feki F; Weckhuysen S; Masmoudi S; Fakhfakh F
    Epilepsia Open; 2024 Jun; 9(3):906-917. PubMed ID: 37701975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.
    Van Bergen NJ; Massey S; Quigley A; Rollo B; Harris AR; Kapsa RMI; Christodoulou J
    Biochem Soc Trans; 2022 Aug; 50(4):1207-1224. PubMed ID: 35997111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
    Leonard H; Junaid M; Wong K; Demarest S; Downs J
    Epilepsy Res; 2021 Jan; 169():106521. PubMed ID: 33341033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKL5 Deficiency Disorder Without Epilepsy.
    Aznar-Laín G; Fernández-Mayoralas DM; Caicoya AG; Rocamora R; Pérez-Jurado LA
    Pediatr Neurol; 2023 Jul; 144():84-89. PubMed ID: 37201242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
    Jhang CL; Lee HY; Chen JC; Liao W
    Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.